

DESCRIPTION

Source Mouse myeloma cell line, NS0-derived
Thr103-Arg227 (Cys156Ser), with a C-terminal 10-His tag
Accession # Q6FH59

N-terminal Sequence Analysis Thr103

Predicted Molecular Mass 15.4 kDa

SPECIFICATIONS

SDS-PAGE 22-24 kDa, reducing conditions

Activity Measured in a cell proliferation assay using HMVEC human microvascular endothelial cells. Marconcini, L. *et al.* (1999) Proc. Natl. Acad. Sci. USA **96**:9671.
The ED₅₀ for this effect is 1-5 µg/mL.

Measured by its binding ability in a functional ELISA.
Immobilized Recombinant Human VEGF R3/FIt-4 Fc Chimera (Catalog # 349-F4) at 5 µg/mL (100 µL/well) can bind Recombinant Human VEGF-C (Cys156Ser) with an apparent K_d <40 nM.

Endotoxin Level <0.10 EU per 1 µg of the protein by the LAL method.

Purity >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Formulation Lyophilized from a 0.2 µm filtered solution in PBS with BSA as a carrier protein. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution Reconstitute at 100 µg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Vascular endothelial growth factor C (VEGF-C) and VEGF-D constitute a subfamily of the angiogenic VEGF angiogenic factors (1). VEGF-C is synthesized as a 58 kDa molecule that consists of a VEGF homology domain (VHD) flanked by N- and C-terminal propeptides. The proprotein undergoes covalent homodimerization and stepwise proteolytic processing to generate ligands with increasing affinity for VEGF R3/FIt-4 (2-4). Fully processed VEGF-C containing just the 21 kDa VHD can additionally bind and activate VEGF R2/KDR/FIk-1 (2, 4). Fully processed human VEGF-C shares 98% amino acid sequence identity with mouse and rat VEGF-C. VEGF-C interactions with VEGF R3 are critical for lymphangiogenesis (5-8). VEGF-C and VEGF R3 are usually co-expressed at sites with lymphatic vessel sprouting, in the embryo, and in various pathological conditions. Over-expression of VEGF-C in tumor cells induces tumoral lymphatic hyperplasia, resulting in enhanced lymph flow and metastasis to regional lymph nodes (9-12). It also induces physiological and intratumoral neoangiogenesis and vessel sprouting through interactions with VEGF R2 (8, 13, 14).

References:

1. Chen, J.-C. *et al.* (2013) Int. J. Mol. Sci. **14**:88.
2. Joukov, V. *et al.* (1996) EMBO J. **15**:290.
3. Kukk, E. *et al.* (1996) Development **122**:3829.
4. Joukov, V. *et al.* (1997) EMBO J. **16**:3898.
5. Karkkainen, M. *et al.* (2004) Nat. Immunol. **5**:74.
6. Jeltsch, M. *et al.* (1997) Science **276**:1423.
7. Makinen, T. *et al.* (2001) Nat. Med. **7**:199.
8. Laakkonen, P. *et al.* (2007) Cancer Res. **67**:593.
9. Hoshida, T. *et al.* (2006) Cancer Res. **66**:8065.
10. Mandriota, S.J. *et al.* (2001) EMBO J. **20**:672.
11. Skobe, M. *et al.* (2001) Nat. Med. **7**:192.
12. Padera, T.P. *et al.* (2002) Science **296**:1883.
13. Tammela, T. *et al.* (2008) Nature **454**:656.
14. Cao, Y. *et al.* (1998) Proc. Natl. Acad. Sci. **95**:14389.